COVID-19对炎症性肠病的影响:发病率、结局及倾向性匹配研究网络分析
基于多机构研究网络TriNetX的回顾性倾向性评分匹配队列研究显示,IBD患者COVID-19发病率低于非IBD人群(发生率比0.79,95%CI 0.72-0.86);IBD合并COVID-19患者住院风险升高(RR 1.17,95%CI 1.02-1.34),机械通气需求和死亡率无差异;使用激素的IBD患者重症监护需求风险升高(RR 2.22,95%CI 1.29-3.82);感染后3个月IBD flare发生率高达7%;COVID-19后新发IBD风险低于非COVID人群(RR 0.64,95%CI 0.54-0.65)。
要点
- IBD患者COVID-19发病率低于非IBD人群,发生率比0.79(95%CI 0.72-0.86)。
- IBD合并COVID-19患者住院风险升高(RR 1.17,95%CI 1.02-1.34),机械通气及死亡率无差异。
- 使用激素的IBD患者重症监护需求风险升高(RR 2.22,95%CI 1.29-3.82)。
核心结论
- IBD患者COVID-19风险未见增加,COVID-19感染后新发IBD风险亦未见增加。
- 研究证实了既往观察到的激素使用对IBD患者COVID-19严重程度的影响。
研究设计与样本
- 回顾性倾向性评分匹配队列研究,利用多机构研究网络TriNetX。
- 识别合并与不合并IBD的COVID-19患者,量化IBD患者COVID-19风险、COVID-19结局及对IBD病程的影响。
- 比较COVID-19患者与非COVID-19人群在相似时间段内新发IBD的风险。
主要发现
- IBD患者COVID-19发生率比低于非IBD人群(0.79,95%CI 0.72-0.86)。
- IBD合并COVID-19患者住院风险较非IBD人群升高(RR 1.17,95%CI 1.02-1.34),机械通气需求或死亡率无差异。
- 使用激素的IBD患者重症监护需求风险升高(RR 2.22,95%CI 1.29-3.82)。
- 高达7%的IBD合并COVID-19患者在感染后3个月发生IBD flare。
- COVID-19后新发IBD风险低于非COVID人群(RR 0.64,95%CI 0.54-0.65)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate estimates for the risk of COVID-19 in IBD, and an understanding of the impact of COVID-19 on IBD course and the risk of incident post-infectious IBD are needed. AIMS: To estimate the risk of COVID-19 in IBD and study its impact on IBD course and the risk of incident post-infectious IBD. METHODS: A retrospective propensity score matched cohort study utilising multi-institutional research network TriNetX. COVID-19 patients with and without IBD were identified to quantify the risk of COVID-19 in patients with IBD, COVID-19 outcomes in patients with IBD and the impact of COVID-19 on IBD disease course. The risk of incident post-infectious IBD in COVID-19 patients was compared to the population not infected with COVID-19 during a similar time period. RESULTS: Incidence rate ratio for COVID-19 was lower in IBD patients compared to the non-IBD population (0.79, 95% CI: 0.72-0.86). COVID-19-infected patients with IBD were at increased risk for requiring hospitalisation compared to non-IBD population (RR: 1.17, 95% CI: 1.02-1.34) with no differences in need for mechanical ventilation or mortality. Patients with IBD on steroids were at an increased risk for critical care need (RR: 2.22, 95% CI: 1.29-3.82). Up to 7% of patients with IBD infected with COVID-19 suffered an IBD flare 3-months post-infection. Risk for incident IBD post-COVID was lower than that seen in the non-COVID population (RR: 0.64, 95% CI: 0.54-0.65). CONCLUSION: We observed no increase in risk for COVID-19 amongst patients with IBD or risk for de novo IBD after COVID-19 infection. We confirmed prior observations regarding the impact of steroid use on COVID-19 severity in patients with IBD.
引用
- Hadi Y, Dulai PS, Kupec J, et al. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Aliment Pharmacol Ther. 2021. PMID: 34904240. doi:10.1111/apt.16730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。